Clinical trial
Study of TPI 287 Administered Every 21 Days in Patients With Advanced…
NCT00256191 · Cortice Biosciences, Inc., Industry · Completed
Key facts
| NCT number | NCT00256191 |
|---|---|
| Title | Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies |
| Official title | A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies |
| Lead sponsor | Cortice Biosciences, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Hodgkin's Disease, Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | TPI 287 Injection |
| Enrollment | 45 |
| Start date | Nov 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | Nov 21, 2005 |
| Last update posted | Oct 15, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: